Neuropacs Announces the Publication of a New Study Comparing the First‑of‑Its‑Kind FDA De Novo–Classified Imaging Biomarker for Parkinson’s Disease with CSF Alpha‑Synuclein Seed Amplification Assay - Business Wire

Neuropacs Announces the Publication of a New Study Comparing the First‑of‑Its‑Kind FDA De Novo–Classified Imaging Biomarker for Parkinson’s Disease with CSF Alpha‑Synuclein Seed Amplification Assay    Business Wire

Original source: Google News